At a glance
ClinicalIndex Comparison RecordN/ARecruiting· 610 target
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Extension Study for Collecting Long-term Follow-up Data of Subjects Enrolled in Clinical Trials of Cadonilimab (AK104)
In Brief
An observational study for Locally Advanced Unresectable or Metastatic Gastric Cancer. Currently recruiting, targeting 610 participants across 1 site.
Detailed Summary
This is an observational and non-interventional clinical study that only collects long-term follow-up data of the subjects. As the world's first approved PD-1/CTLA-4 bispecific antibody for marketing, Cadonilimab may confer long-term survival benefits.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesChina
Collaborators--
Timeline
N/ARecruiting
20252026202720282029203020312032203320342035203620372038203920402041
Enrollment StartDec 2024
First PostedApr 2026
TodayJul 2026
Primary CompletionDec 2030
Study CompletionDec 2040
First PostedApr 23, 2026
Enrollment StartDec 26, 2024
Primary CompletionDec 31, 2030
Study CompletionDec 31, 2040
TodayJul 1, 2026
Enrollment to primary: 6.0 yearsPosted 2 months agoPrimary completion in 4.5 years